325 related articles for article (PubMed ID: 19240944)
21. The unique biological features of the marine product Yondelis (ET-743, trabectedin) are shared by its analog ET-637, which lacks the C ring.
Erba E; Cavallaro E; Damia G; Mantovani R; Di Silvio A; Di Francesco AM; Riccardi R; Cuevas C; Faircloth GT; D'Incalci M
Oncol Res; 2004; 14(11-12):579-87. PubMed ID: 15666999
[TBL] [Abstract][Full Text] [Related]
22. DNA sequence- and structure-selective alkylation of guanine N2 in the DNA minor groove by ecteinascidin 743, a potent antitumor compound from the Caribbean tunicate Ecteinascidia turbinata.
Pommier Y; Kohlhagen G; Bailly C; Waring M; Mazumder A; Kohn KW
Biochemistry; 1996 Oct; 35(41):13303-9. PubMed ID: 8873596
[TBL] [Abstract][Full Text] [Related]
23. Going further in the knowledge of Yondelis®; what's new in clinical trials?
Blay JY
Future Oncol; 2014 Jun; 10(8 Suppl):s7-s12. PubMed ID: 25048046
[TBL] [Abstract][Full Text] [Related]
24. A review of trabectedin (ET-743): a unique mechanism of action.
D'Incalci M; Galmarini CM
Mol Cancer Ther; 2010 Aug; 9(8):2157-63. PubMed ID: 20647340
[TBL] [Abstract][Full Text] [Related]
25. Meta-omic characterization of the marine invertebrate microbial consortium that produces the chemotherapeutic natural product ET-743.
Rath CM; Janto B; Earl J; Ahmed A; Hu FZ; Hiller L; Dahlgren M; Kreft R; Yu F; Wolff JJ; Kweon HK; Christiansen MA; Håkansson K; Williams RM; Ehrlich GD; Sherman DH
ACS Chem Biol; 2011 Nov; 6(11):1244-56. PubMed ID: 21875091
[TBL] [Abstract][Full Text] [Related]
26. Advances in the chemistry and pharmacology of ecteinascidins, a promising new class of anti-cancer agents.
Manzanares I; Cuevas C; García-Nieto R; Marco E; Gago F
Curr Med Chem Anticancer Agents; 2001 Nov; 1(3):257-76. PubMed ID: 12678757
[TBL] [Abstract][Full Text] [Related]
27. Dual inhibition of ATR and ATM potentiates the activity of trabectedin and lurbinectedin by perturbing the DNA damage response and homologous recombination repair.
Lima M; Bouzid H; Soares DG; Selle F; Morel C; Galmarini CM; Henriques JA; Larsen AK; Escargueil AE
Oncotarget; 2016 May; 7(18):25885-901. PubMed ID: 27029031
[TBL] [Abstract][Full Text] [Related]
28. Biology of ovarian cancer and trabectedin mechanism of action.
Ray-Coquard I
Future Oncol; 2013 Dec; 9(12 Suppl):11-7. PubMed ID: 24195525
[TBL] [Abstract][Full Text] [Related]
29. Synthesis of ecteinascidin ET-743 and phthalascidin Pt-650 from cyanosafracin B.
Cuevas C; Pérez M; Martín MJ; Chicharro JL; Fernández-Rivas C; Flores M; Francesch A; Gallego P; Zarzuelo M; de La Calle F; García J; Polanco C; Rodríguez I; Manzanares I
Org Lett; 2000 Aug; 2(16):2545-8. PubMed ID: 10956543
[TBL] [Abstract][Full Text] [Related]
30. Yondelis (trabectedin, ET-743): the development of an anticancer agent of marine origin.
van Kesteren Ch; de Vooght MM; López-Lázaro L; Mathôt RA; Schellens JH; Jimeno JM; Beijnen JH
Anticancer Drugs; 2003 Aug; 14(7):487-502. PubMed ID: 12960733
[TBL] [Abstract][Full Text] [Related]
31. Synthetic studies on Et-743. Assembly of the pentacyclic core and a formal total synthesis.
Fishlock D; Williams RM
J Org Chem; 2008 Dec; 73(24):9594-600. PubMed ID: 18687003
[TBL] [Abstract][Full Text] [Related]
32. ET-743 (PharmaMar/NCI/Ortho Biotech).
Verschraegen CF; Glover K
Curr Opin Investig Drugs; 2001 Nov; 2(11):1631-8. PubMed ID: 11763168
[TBL] [Abstract][Full Text] [Related]
33. Trabectedin and its C subunit modified analogue PM01183 attenuate nucleotide excision repair and show activity toward platinum-resistant cells.
Soares DG; Machado MS; Rocca CJ; Poindessous V; Ouaret D; Sarasin A; Galmarini CM; Henriques JA; Escargueil AE; Larsen AK
Mol Cancer Ther; 2011 Aug; 10(8):1481-9. PubMed ID: 21622731
[TBL] [Abstract][Full Text] [Related]
34. In vitro antitumor activity of the novel marine agent, ecteinascidin-743 (ET-743, NSC-648766) against human tumors explanted from patients.
Izbicka E; Lawrence R; Raymond E; Eckhardt G; Faircloth G; Jimeno J; Clark G; Von Hoff DD
Ann Oncol; 1998 Sep; 9(9):981-7. PubMed ID: 9818072
[TBL] [Abstract][Full Text] [Related]
35. Sea squirt assaults sarcomas.
Burton A
Lancet Oncol; 2002 Nov; 3(11):648. PubMed ID: 12424055
[No Abstract] [Full Text] [Related]
36. Recent synthetic approaches to 6,15-iminoisoquino[3,2-b]3-benzazocine compounds.
Avendaño C; de la Cuesta E
Chemistry; 2010 Aug; 16(32):9722-34. PubMed ID: 20533463
[TBL] [Abstract][Full Text] [Related]
37. Poisoning of human DNA topoisomerase I by ecteinascidin 743, an anticancer drug that selectively alkylates DNA in the minor groove.
Takebayashi Y; Pourquier P; Yoshida A; Kohlhagen G; Pommier Y
Proc Natl Acad Sci U S A; 1999 Jun; 96(13):7196-201. PubMed ID: 10377391
[TBL] [Abstract][Full Text] [Related]
38. Studies directed to the total synthesis of ET 743 and analogues thereof: an expeditious route to the ABFGH subunit.
Zhou B; Guo J; Danishefsky SJ
Org Lett; 2002 Jan; 4(1):43-6. PubMed ID: 11772086
[TBL] [Abstract][Full Text] [Related]
39. Structure elucidation and 1H/13C NMR spectral assignments of four trabectedin related compounds.
Vermeulen W; Filliers W; García C; Manzanaro S; Montalvo D; Polanco C; Spillemaeckers F; Van Hoof B; Winderickx G; Somers I; Rodriguez-Campos I
Magn Reson Chem; 2008 Dec; 46(12):1198-202. PubMed ID: 18821578
[TBL] [Abstract][Full Text] [Related]
40. Fetal bovine serum, but not human serum, inhibits the in vitro cytotoxicity of ET-743 (Yondelis, trabectedin), an example of potential problems for extrapolation of active drug concentrations from in vitro studies.
Tognon G; Frapolli R; Zaffaroni M; Erba E; Zucchetti M; Faircloth GT; D'Incalci M
Cancer Chemother Pharmacol; 2004 Jan; 53(1):89-90. PubMed ID: 14586558
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
